



Mia[®]: AI in breast cancer screening and safety considerations.

Carla Brackstone - Partnerships Manager
July 2022

Contents

- Introduction to Kheiron and Mia
- Safety considerations and initiatives



Introduction

Kheiron Medical Technologies


- Small/medium UK AI startup founded in 2016
- Focus on breast screening
- Clinical rigour and robust evidence generation




"Giving any woman, anywhere a better fighting chance against breast cancer"

Introduction


Challenges in breast screening programmes



High stress,
cognitive load,
burnout



Unnecessary
recalls, poor
participant
experience



Shortage of
trained breast
radiologists

MiaTM


By Kheiron Medical

Giving **any** woman, **any**where a better fighting
chance against breast cancer

Mia[®] is our breakthrough AI platform for breast screening.
A suite of solutions, Mia is designed to empower radiologists
and screening services to deliver confident, accurate and
timely results to any woman, anywhere.

Introduction

Breast cancer screening solutions along the clinical pathway



Introduction


Mia as an independent reader




Case-Wise Recall Suggestion

Mia™ suggests a decision for the entire case, just like asking a radiologist

Historical Double Reading



Double Reading with Mia™




Introduction

First winner of UK Government's AI in Health and Care Award 2020

- Evidence generation – national policy
- Independent evaluation
- Clinical confidence – trusted by Radiologists and readers
- Genuine patient and public involvement and support
- Generalisability
- Retrospective Study
- Prospective Study
- Safely deploy Mia into NHS Breast Screening

The AI in Health and Care Award
Congratulations to innovators





Safety considerations and initiatives

9

Safety considerations

Data protection

- **Pseudonymisation** of patient information before extracting from sites or being handled by Mia
- Worked closely with **data protection consultants** to generate data protection positioning and supporting documentation
 - Supporting NHS Trust IG teams to ensure comfort and compliance
- Involvement in ICO workshops to help **drive the agenda on information governance in AI**
- **Strict security and privacy processes** and procedures to ensure that pseudonymised patient information is handled safely
- **Appropriate consent models** as and when prospective data will be used for research



Safety considerations

Regulatory and standards compliance

- **CE marked** - class IIa medical device
- **ISO 13485** (quality management system standard for medical devices), **14971** (standard for risk management) and **62304** (standards on software lifecycle process/development) compliant
- Protocols designed to comply with NHS Digital standards, **DCB0129 and DCB0160**
- Protocols designed to comply with **CONSORT-AI, SPIRIT-AI and DECIDE-AI guidelines**



Safety considerations

Deployment methodology

1. Understand

Understand your clinical and business objectives, workflow, processes & technical environment.

2. Connect

Connect your systems to the Mia cloud & configure your workflows. Test end-to-end.

3. Validate (live data first, historical data if required)

Check Mia's performance with local population & data.

4. Train

Train clinical & administrative teams to work confidently with Mia.

5. Launch (live data)

Put approvals, processes and communications in place. Go live.

**Mia goes live, used within
clinical care setting**

6. Monitor (live data)

Continuously monitor performance and impact.


Safety considerations

Patient and Public Involvement (PPI)

By engaging with the people who are impacted by breast cancer we are able to focus our products on solving the problems they care about.

Our PPI efforts have been cited as **industry leading** and include:


- **A PPI Advisory Board** curates the insight, knowledge, and experience to guide product development and deployment
- **Literature review and interviews** to enlighten our understanding of attitudes and beliefs around the adoption of AI in screening
- **Collaboration with PPI Leads at hospitals** to ensure all views are represented in what we deliver
- Co-designing **high quality information materials** to educate, inform, and engage women about our work



Safety considerations

Generalisability

- Previous run trial was across 7 sites and two countries using;
 - **unenriched data**, representative of real world screening populations & **clinically relevant** endpoints
- AI Award will build on this across the UK
 - including building **prospective evidence and monitoring processes**
 - government funded UK wide collaborative partnerships
- Reducing algorithmic bias
 - partners that cover all **ethnicities and demographics**
- Global partners and **active research**
 - RSNA panel - importance of **inclusivity and diversity** in healthcare AI



The AI in Health and Care Award
Congratulations to innovators



Clinical evidence – retrospective study

250,000+
cases




180,000+
women



7 sites



Key endpoints




20+
stratifications
INCLUDING:

Vendor



Consistent performance
demonstrated across 4
mammography device
manufacturers

Invasivity




Insights into performance
for aggressive cancers

Prevalent/Incident



Performance on first
screening visit

Tumor Size



Safety considerations

Case study work with NHS Digital and AAIP

- Involvement as a case study in the **Safety Assurance Framework for Machine Learning in the Healthcare Domain (SAFR)** project
- Including a detailed review of the **Assurance of Machine Learning in Autonomous Systems (AMLAS)** framework
- Contextual review of the CIEHF **Human Factors and Ergonomics in Healthcare AI**
- **Clinical Risk Management Training - Assuring AI in Healthcare** Training day

**ASSURING
AUTONOMY**
INTERNATIONAL PROGRAMME

NHS
Digital





Thank you

carla@kheironmed.com

